Campylobacter

Campylobacter are kind of gram-negative bacteria were first recognized in the early 1900s. A few decades later, the organism was occasionally reported as a cause of human disease. The new genus, Campylobacter spp. was named in 1973. However, it was not until the 1980s that researchers began to recognize the wide-ranging impact of Campylobacter infections on human health, and it is now known to be an important pathogen causing acute diarrhoea and systemic diseases worldwide. Campylobacter spp. are frequently found in the gastrointestinal tracts of animals, particularly poultry. As a result, infections are often transmitted from animals to humans.

Epidemiology

Campylobacteriosis

• Ninety percent of human diseases caused by Campylobacter are caused by C. jejuni, with most of the remainder attributed to C. coli.
• The main clinical manifestations of Campylobacter infection in humans include abdominal pain, watery or bloody diarrhea, and chills, a large number of leukocytes and erythrocytes seen in the stool.
• Globally, the incidence of campylobacteriosis varies considerably from country to country and region to region, and its true incidence is largely unknown, especially in developing countries.

Antimicrobial Resistance

Empirical clinical treatment of infectious often involves the use of antibiotics, such as fluoroquinolones and macrolides. However, the emergence of multidrug-resistant Campylobacter and the increasing degree of resistance pose significant challenges to clinical drug use.

Mechanisms of antibiotic resistance

Studies delving into the resistance mechanisms have revealed strategies such as point mutation in pertinent genes, efflux pumps, and plasmid-enabled resistance.

Treatment Options

Antibiotic therapy

Fluoroquinolones and macrolides are commonly used in clinical treatment as antibiotics.

Potential options

• Utilizing natural products
• Implementing phage therapy
• Employing vaccine strategy
• Applying antimicrobial peptides

Our Capabilities

Ace Therapeutics is dedicated to unraveling the complexity of Campylobacter, exploring the mechanisms of Campylobacter resistance, and seeking new potential targets. Our related services include.

• Genome Sequencing and Analysis

We provide whole genome sequence analysis using the latest sequencing technologies and perform multiple analyses of Campylobacter strains to help identify genetic factors associated with antibiotic resistance.

• Drug Development Services

Our pharmaceutical research team is dedicated to discovering effective compounds that target Campylobacter, thereby reducing the likelihood of resistance.

• Collaborative Research Program

We collaborate with research organizations, public health entities and pharmaceutical companies to accumulate resources and strive for excellence. It is our belief to facilitate the exchange of knowledge.

In Conclusion

Antimicrobial-resistant Campylobacter poses a serious threat to public health. Clonal amplification of drug-resistant strains and horizontal spread of drug-resistant genes may hamper the clinical efficacy of antibiotic therapy for Campylobacteriosis. We therefore need to adopt a diversified strategy.

Reference

1. Liu F; et al. (2022). Global epidemiology of campylobacteriosis and the impact of COVID-19. Front Cell Infect Microbiol. 28(12):979055.